Clinical Trial

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

Name: Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation — clinical trial record (NCT07158710)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.

Trial Details

NCT Number	NCT07158710
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	Malignant Brain Tumors
Enrollment	159 participants
Start Date	2025-08-15
Primary Completion	2029-05-23 (estimated)
Study Completion	2029-12-03 (estimated)
Updated on ClinicalTrials.gov	2025-09-08